Share this article
Share this article
ResearchAndMarkets.com's offering.
The report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.
Overview
Since the success of ADCETRIS (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions.